Steven H. Holtzman is a founder, and has served as Infinity's Chief Executive Officer since the Company's inception. From early 1994 through mid 2001, Mr. Holtzman served as the Chief Business Officer of Millennium Pharmaceuticals. In this role, at various times he had management responsibility for the Company's activities in the areas of: business development, M&A, licensing, intellectual property and corporate law, human resources, finance, corporate and government affairs, bioethics, public policy, media relations, investor relations, and corporate communications.

Prior to joining Millennium, from 1986-1994, Mr. Holtzman was a founder, the first employee, and Executive Vice President of DNX Corporation, the first commercial enterprise devoted to the development of agricultural, biomedical, and pharmaceutical applications of transgenic animal technology. Prior to DNX, in the early 1980's, Mr. Holtzman conceived of and was the founding Executive Director of the Ohio Edison Program, the nation's first state government program directed to achieving economic development through funding young technology-based ventures and university/industry collaborative research and development efforts. In the late 1970's, Mr. Holtzman was an instructor and tutor in moral philosophy and the philosophy of language at Corpus Christi College, Oxford University, U.K.

Mr. Holtzman co-founded and from 1995-2000 was the Co-Chair of the Biotechnology Industry Organization (BIO) Bioethics Committee. From 1996-2001, he served as a presidential appointee to the National Bioethics Advisory Commission, the principal advisory body to the President and Congress on ethical issues in the biomedical and life sciences. He is a member of the Board of Directors of Anadys Pharmaceuticals, Inc. He is a Trustee of The Hastings Center for Bioethics and a Trustee of the Berklee College of Music. Mr. Holtzman received his B.A. in Philosophy from Michigan State University and his B.Phil. graduate degree in Philosophy from Oxford University, which he attended as a Rhodes Scholar.

Anthony B. Evnin, Ph.D., Chair of Infinity's Compensation Committee, has served as Managing General Partner of Venrock Associates since 1980. and has been employed by Venrock Associates since 1974. Dr. Evnin also serves as a director of several private companies, as well as the following publicly-traded biopharmaceutical companies: Icagen, Inc.; Memory Pharmaceuticals Corp.; Pharmos Corporation; Renovis, Inc.; Coley Pharmaceuticals, Inc.; and Sunesis Pharmaceuticals, Inc. Dr. Evnin received an A.B. in Chemistry from Princeton University and a Ph.D. in Chemistry from the Massachusetts Institute of Technology.

Eric S. Lander, Ph.D., was a co-founder of Infinity, and served as a member of its board of directors since 2001. Dr. Lander has been a Professor and Associate Professor of Biology at the Massachusetts Institute of Technology since 1990 and a Professor of Systems Biology at Harvard Medical School since 2004. Dr. Lander has served as the founding Director of The Eli and Edythe L. Broad Institute, a biomedical research institute formed by MIT and Harvard University, since 2003 and as a member of the Whitehead Institute for Biomedical Research since 1989. From 1993 to 2003, Dr. Lander was the Director of the Whitehead/MIT Center for Genome Research. Dr. Lander is a founder and serves as a director of Millennium Pharmaceuticals, Inc., a publicly traded pharmaceutical company. Dr. Lander received an A.B. in Mathematics from Princeton University and a D.Phil. in Mathematics from Oxford University, which he attended as a Rhodes Scholar.

Arnold J. Levine, Ph.D., lead Research & Development Director, is a Professor at The Cancer Institute of New Jersey, Robert Wood Johnson School of Medicine and a Professor at the Institute for Advanced Study. From 1998 to 2002, Dr. Levine was President of Rockefeller University. Prior to joining Rockefeller University, Dr. Levine was the Harry C. Weiss Professor in the Life Sciences and Chairman of the Department of Molecular Biology at Princeton University from 1984 to 1996. Dr. Levine also serves as a director of Theravance, Inc., and Applera Corporation, publicly-traded life science companies. Dr. Levine received a B.A. in Biology from Harpur College, State University of New York at Binghamton and a Ph.D. in Microbiology from The University of Pennsylvania.

Vicki L. Sato, Ph.D., Lead Outside Director, is currently a professor at Harvard University. From 1992 to 2005, Dr. Sato held various positions with Vertex Pharmaceuticals, Inc., a publicly-traded pharmaceutical company, most recently serving as President from 2000 to 2005. Prior to joining Vertex Pharmaceuticals, Inc., from 1984 to 1992, Dr. Sato held various positions with Biogen, Inc., a publicly traded biotechnology company, most recently serving as Vice President of Research and a member of the Scientific Advisory Board. Since 1993, Dr. Sato has served on the Board of Tutors, Department of Biochemistry and Molecular Biology at Harvard University, and also served as an Assistant Professor and Associate Professor in the Department of Biology at Harvard University from 1975 to 1983. Dr. Sato is a business advisor to Atlas Ventures, a venture capital firm, and other enterprises in the biotechnology and pharmaceutical industries. Dr. Sato serves as an overseer of the Isabella Stewart Gardner Museum and is a trustee of Jose Mateo's Ballet Theatre. Dr. Sato serves as a director of Bristol-Myers Squibb Company and Alnylam Pharmaceuticals, Inc., publicly traded biopharmaceutical companies, and Perkin-Elmer, Inc., a diversified company with businesses in the life and analytical sciences and optoelectronics. Dr. Sato received an A.B. in Biology from Radcliffe College and a M.A. and Ph.D. in Biology from Harvard University.

Michael C. Venuti, Ph.D.,is currently CEO of BioSeek, Inc. Dr. Venuti was formerly an Operating Partner at TPG Growth Biotech Ventures. Prior to TPG, he was the former Acting Chief Executive Officer and Chief Scientific Officer of Discovery Partners International, Inc. (DPI) with which Infinity merged in September 2006. Dr. Venuti had served as a member of the DPI Board of Directors since May 2003, and joined DPI as Chief Scientific Officer in April 2005. Prior to that, he was Senior Vice President of Pharmacogenomics, and was named Senior Vice President of Research and General Manager of Celera South San Francisco when Applera Corporation-Celera Genomics Group acquired Axys Pharmaceuticals in 2001. From 1994 through 2001, Dr. Venuti was Director of Medicinal Chemistry, and then Chief Technical Officer, for Axys Pharmaceuticals and its predecessor company, Arris Pharmaceutical Corporation, where he had overall responsibility for ten major pharma collaborations, and was responsible for the founding of a profitable combinatorial chemistry business later sold to Discovery Partners.

From 1988-1993, Dr. Venuti was Director of Bioorganic Chemistry at Genentech, Inc., leading the first group of medicinal chemists established in biotech to exploit the tools of recombinant DNA-based technology as applied to drug discovery. From 1980-1988, at Syntex Research, he led a medicinal chemistry group in the areas of enzyme inhibition and biochemical probes.

Dr. Venuti was educated at the Boston Latin School (1971), Dartmouth College (A.B., 1975), Massachusetts Institute of Technology (Ph.D., Organic Chemistry, 1979), and completed postdoctoral training at The Institute of Organic Chemistry at Syntex Research, Palo Alto, California. Dr. Venuti has also held an appointment as Adjunct Professor of Chemistry in the Department of Pharmaceutical Chemistry at the University of California, San Francisco, since 1992.